Eric Faulkner is a globally recognized executive in innovative technology evidence development, value demonstration, access and commercialization with >25 years of experience.
Most recently he has recently, he has served as President of Passage Health Associates, Chief Scientific Officer of SymetryML a breakthrough AI/ML data sharing platform, and Vice President and Exec Value and Access Team at Novartis Gene Therapies supporting the world’s leading gene therapy scale to >$2B spanning 55+ markets. Experience includes co-founding a top 5 RWE function for a leading CRO and multiple cross-function Centers of Excellence in emerging biopharma and device technology growth areas for IQVIA and Thermofisher/PPD.
Mr. Faulkner is a recognized global thought leader in emerging technology evidence development, product access and patient/health system uptake, including >750 strategic peri- and post-approval scenarios. Eric has helped companies navigate multiple 1st in the world product market access and commercial scenarios with limited or no global precedent.
His service includes Board, leadership, committee and special interest group work as a co-founder of ACCESS Forum and the World ACCESS Consortium, and Executive Director of NAMCPs Genomics Biotech and and Emerging Medical Technology Institutes, as well as service to ARM, ARM Foundation, ASGCT, ISCT, ISPOR, Cure Rare Disease, Global Genes, the President’s Council for Advisors on Science and Technology (PCAST), 90/10 Institute, Duke University’s Margolis Institute, MIT’s NewDIGs, ONCOTyrol, and others. He also serves as Assistant Professor at the University of North Carolina at Chapel Hill.